PKMYT1

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Retrieved on: 
월요일, 11월 7, 2022
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Roche, PKMYT1, Company, DNA, Therapy, CRISPR, IND, Genome, View, ATR, Pharmaceutical industry

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in November.
  • Details for the fireside chats are as follows:
    A live webcast of the fireside chats can be accessed in the Investor section of the Companys website at https://ir.reparerx.com/news-and-events/events .
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005156/en/

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Retrieved on: 
수요일, 9월 7, 2022
Biotechnology, General Health, Other Health, Health, Oncology, DNA, Genome, Therapy, Roche, ATR, CRISPR, IND, PKMYT1, View, Company, Pharmaceutical industry

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September.
  • Details for the fireside chats are as follows:
    A live webcast of the fireside chats can be accessed in the Investor section of the Companys website at https://ir.reparerx.com/news-and-events/events .
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005031/en/

Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on: 
목요일, 8월 4, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, U.S. Securities and Exchange Commission, Exercise, Risk, ATR, Forward-looking statement, Bristol Myers Squibb, Private Securities Litigation Reform Act, SEC, Security (finance), Research, AMF, Neoplasm, FOLFIRI, Patient, Therapy, COVID-19, Company, Net, DNA, PKMYT1, Genome, Safety, CRISPR, AACR, Operational definition, Pharmaceutical industry, Medical imaging, Fine chemical, IND, Reparenting, G&A

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the second quarter ended June 30, 2022.
  • In connection with the closing of the collaboration agreement, Repare received an upfront payment of $125 million from Roche in July 2022.
  • Second Quarter 2022 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of June 30, 2022 were $282.1 million, which excludes the $125 million now received from Roche and extends cash runway into 2026.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics to Participate at the Goldman Sachs 43rd Annual Global Healthcare Conference

Retrieved on: 
화요일, 6월 7, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, CA, Company, Conference, Webcast, CRISPR, Therapy, Goldman, Genome, ATR, DNA, PKMYT1, View, Goldman Sachs, Pharmaceutical industry

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022 at 03:20 p.m. Pacific Time/ 6:20 p.m. Eastern Time in Rancho Palos Verdes, CA.
  • A live webcast of the fireside chat can be accessed in the Investor section of the Companys website at https://ir.reparerx.com/news-and-events/events .
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005384/en/

Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)

Retrieved on: 
수요일, 6월 1, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Exercise, Leadership, Company, Business, Corporation, EVP, Forward-looking statement, Roche, CRISPR, Security (finance), U.S. Securities and Exchange Commission, ATM, Therapy, Risk, Patient, Cancer, Private Securities Litigation Reform Act, Genome, ATR, AMF, DNA, COVID-19, PKMYT1, Hart–Scott–Rodino Antitrust Improvements Act, SEC, Neoplasm, Safety, Pharmaceutical industry, Reparenting

Under the collaboration, Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies.

Key Points: 
  • Under the collaboration, Roche will assume development of camonsertib with the potential to expand development into additional tumors and multiple combination studies.
  • We are looking forward to partnering with Repare Therapeutics to further develop camonsertib as a new potential treatment option for patients with significant unmet medical needs across a range of tumor types.
  • The collaboration with Repare builds on Roches strategy of personalized healthcare and further strengthens our leadership in oncology.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day

Retrieved on: 
월요일, 5월 9, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Company, View, ATR, CRISPR, Webcast, Therapy, Genome, DNA, PKMYT1, Pharmaceutical industry

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
  • A live webcast of the fireside can be accessed in the Investor section of the Companys website at https://ir.reparerx.com/news-and-events/events .
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • SNIPRx is a registered trademark of Repare Therapeutics Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005181/en/

Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
목요일, 5월 5, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Treatment, ATR, Parpi, Toxicity, CA125, Safety, Circulating tumor DNA, CBR, Atri, Risk, CCNE1, Net, CRISPR, SEC, FOLFIRI, LOF, Melanoma, Forward-looking statement, Company, CPSA, Breast cancer, EVP, Patient, BRCA2, Clinical trial, Neoplasm, STEP2, Anemia, Ovarian cancer, Research, ORR, PARP, ATM, Therapy, U.S. Securities and Exchange Commission, AMF, Private Securities Litigation Reform Act, Security (finance), International, Genome, USAN, DNA, PKMYT1, AACR, Operational definition, Toxic leukoencephalopathy, COVID-19, Head, BRCA1, Ataxia–telangiectasia, RECIST, Platinum, Commercial, Data, Progression-free survival, G&A, Pharmaceutical industry, Medical imaging, Nature, Reparenting

Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
  • Overall clinical benefit rate (CBR) for all patients was 43%, and 47% in patients after PARP inhibitor (PARPi) failure.
  • First Quarter 2022 Financial Results:
    Cash and cash equivalents and marketable securities: Cash and cash equivalents and marketable securities as of March 31, 2022 were $311.7 million.
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Retrieved on: 
수요일, 4월 20, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DNA, Clinical trial, PKMYT1, ISCB Senior Scientist Award, U.S. Securities and Exchange Commission, COVID-19, Security (finance), University, Research, MD, ATR, Private Securities Litigation Reform Act, Genome, Lunenfeld-Tanenbaum Research Institute, Doctor of Philosophy, Risk, Patient, Department, EVP, Mount Sinai Health System, CCNE1, Company, CIHR, Therapy, SEC, Forward-looking statement, Neoplasm, Durocher, FOLFIRI, Safety, Public, Senior, CRISPR, AMF, Canadian Institutes of Health Research, Antibiotics, Pharmaceutical industry, Nature, Neurological reparative therapy

SNIPRx, Repares proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.

Key Points: 
  • SNIPRx, Repares proprietary, genome-wide, CRISPR-based screening approach, was used to uncover CCNE1 amplification as synthetic lethal to PKMYT1 inhibition.
  • RP-6306 is a first-in-class and highly selective PKMYT1 inhibitor, and these preclinical data show its ability to target CCNE1-amplfied tumors and profoundly inhibit tumor growth, said Michael Zinda, PhD, EVP and Chief Scientific Officer of Repare.
  • This led to the identification of a previously uncharacterized vulnerability to PKMYT1 inhibition that spurred the development of RP-6306 by Repare Therapeutics."
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.

Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting

Retrieved on: 
월요일, 4월 11, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, Treatment, Private Securities Litigation Reform Act, Therapy, Clonal hematopoiesis, Research, Risk, SEC, Head, Progression-free survival, Medical director, MBBS, Neoplasm, Ataxia–telangiectasia, MD, SETD2, Data, AMF, ATM, CPSA, CRISPR, Security (finance), ORR, BRCA2, Anemia, CHIP, Institute, U.S. Securities and Exchange Commission, Department, MD Anderson Cancer Center, PKMYT1, PARP, Talazoparib, DNA, Forward-looking statement, LOF, Clinical trial, Pharmacokinetics, RECIST, FRCP, Doctor of Philosophy, ATR, Ovarian cancer, STEP2, Associate professor, Melanoma, Patient, Company, BRCA1, Genome, Parpi, RAD51C, Platinum, PFS, CA125, Safety, CBR, COVID-19, Breast cancer, Division, Pharmaceutical industry, Medical imaging, Reparenting

Our comprehensive new dataset shows ATM loss of function as a compelling opportunity to offer durable clinical benefit to patients with genetically defined tumors.

Key Points: 
  • Our comprehensive new dataset shows ATM loss of function as a compelling opportunity to offer durable clinical benefit to patients with genetically defined tumors.
  • The Company will subsequently host a conference call today, April 11th at 6:30 p.m. Eastern Time to discuss the latest results from the TRESR trial.
  • Key highlights from the data presented at the 2022 AACR Annual Meeting include:
    RP-3500 monotherapy continues to appear safe and well tolerated.
  • Clinical benefit was also observed in patients with tumors harboring BRCA1 and BRCA2 genomic alterations, as predicted by SNIPRx.

Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting

Retrieved on: 
금요일, 4월 8, 2022
Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Company, Private Securities Litigation Reform Act, Therapy, Genome, DNA, Forward-looking statement, Clinical trial, FRCP, Research, Risk, Doctor of Philosophy, SEC, ATR, Medical director, MBBS, U.S. Securities and Exchange Commission, Neoplasm, Safety, Institute, COVID-19, Associate professor, Reparenting, AMF, Department, MD Anderson Cancer Center, PKMYT1, CRISPR, Division, Patient, Security (finance), Pharmaceutical industry

The Company will host a conference call with accompanying slides for analysts and investors on Monday, April 11, 2022 at 6:30 p.m. Eastern Time to further discuss the RP-3500 data presented at the 2022 AACR Annual Meeting.

Key Points: 
  • The Company will host a conference call with accompanying slides for analysts and investors on Monday, April 11, 2022 at 6:30 p.m. Eastern Time to further discuss the RP-3500 data presented at the 2022 AACR Annual Meeting.
  • A live video webcast will be available in the Investor section of the Companys website at https://ir.reparerx.com/news-and-events/events .
  • Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics.
  • These forward-looking statements are based on the Companys expectations and assumptions as of the date of this press release.